BioMarin Pharmaceutical
BMRN | NASDAQ
$57.99
+$0.76 (+1.33%)
At close: Nov 16, 2026, 4:00 PM ET
$57.99
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
BioMarin Pharmaceutical Company Profile
Company profile explainedCompany Profile
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Key Executives
| Name | Position |
|---|---|
| Alexander Hardy | President, Chief Executive Officer & Director |
| Amy Wireman | Executive Vice President & Chief People Officer |
| C. Greg Guyer | Executive Vice President & Chief Technology Officer |
| Cara Bauer | Executive Vice President & Chief People Officer |
| George Eric Davis | Executive VP, Chief Legal Officer & Secretary |
| Arpit Dave | Executive Vice President, Chief Digital & Information Officer |
| Brian R. Mueller | CFO & Executive VP of Finance |
| Cristin Hubbard | Executive Vice President & Chief Commercial Officer |
| Ganesh Vedantham | Senior Vice President of Technical Development |
| Gregory Friberg | Executive Vice President and Chief Research & Development Officer |
| Kevin Eggan | Chief Scientific Officer & Senior Vice President of Research and Early Development |
| Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 06, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 4 | Filing |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 4 | Filing |
| Sep 14, 2026 | 3 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 4 | Filing |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 31, 2026 | 8-K | Current Report |
BioMarin Pharmaceutical
| Country | United States |
| IPO Date | Jul 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,221 |
| CEO | Alexander Hardy |
Contact Details
770 Lindaro Street San Rafael,
California 94901 United States
Stock Details
| Ticker Symbol | BMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001048477 |
| CUSIP Number | 09061G101 |
| ISIN Number | US09061G1013 |
| SIC Code | 2834 |
Recent News
- 17 hours ago / marketbeat.comBioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
- 18 hours ago / seekingalpha.comBioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
- 5 days ago / marketbeat.comBioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
- 5 days ago / seekingalpha.comBioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
- 13 days ago / seekingalpha.comBioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
- 13 days ago / prnewswire.comBioMarin to Participate in Upcoming Investor Conferences
- 14 days ago / seekingalpha.comBioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comBioMarin Pharmaceutical Q3 Earnings Call Highlights
- 14 days ago / zacks.comBioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 14 days ago / zacks.comBioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
Add to Watchlist
Select watchlists to add or remove BMRN